X4 Pharmaceuticals, Inc Quarterly Interest Expense in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
X4 Pharmaceuticals, Inc quarterly/annual Interest Expense history and growth rate from Q1 2017 to Q2 2024.
  • X4 Pharmaceuticals, Inc Interest Expense for the quarter ending June 30, 2024 was $2.18M, a 89.5% increase year-over-year.
  • X4 Pharmaceuticals, Inc Interest Expense for the twelve months ending June 30, 2024 was $7.57M, a 71.3% increase year-over-year.
  • X4 Pharmaceuticals, Inc annual Interest Expense for 2023 was $5.78M, a 44.7% increase from 2022.
  • X4 Pharmaceuticals, Inc annual Interest Expense for 2022 was $3.99M, a 9.64% increase from 2021.
  • X4 Pharmaceuticals, Inc annual Interest Expense for 2021 was $3.64M, a 35.5% increase from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $7.57M $2.18M +$1.03M +89.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $6.54M $1.87M +$765K +69% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $5.78M $1.89M +$742K +64.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 $5.04M $1.63M +$616K +60.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $4.42M $1.15M +$230K +25.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $4.19M $1.11M +$196K +21.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $3.99M $1.14M +$218K +23.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 $3.78M $1.02M +$98K +10.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $3.68M $918K +$13K +1.44% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $3.66M $913K +$22K +2.47% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $3.64M $926K +$206K +28.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-21
Q3 2021 $3.44M $920K +$223K +32% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $3.21M $905K +$218K +31.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $3M $891K +$307K +52.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $2.69M $720K +$172K +31.4% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-21
Q3 2020 $2.52M $697K +$9K +1.31% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $2.51M $687K +$175K +34.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $2.33M $584K +$185K +46.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $2.15M $548K +$312K +132% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-17
Q3 2019 $1.84M $688K +$540K +365% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $1.3M $512K +$345K +207% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $950K $399K +$230K +136% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $720K $236K +$1.55M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-19
Q3 2018 -$832K $148K -$195K -56.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$637K $167K -$277K -62.4% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$360K $169K -$850K -83.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 $490K -$1.32M Oct 1, 2017 Dec 31, 2017 10-K 2020-03-12
Q3 2017 $343K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $444K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 $1.02M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.